Akèy › Kasinòm lobilè
Etid klinik pou Kasinòm lobilè ap rekrite nan Etazini
10 etid pou Kasinòm lobilè ap rekrite patisipan nan sit atravè Etazini.
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Ap rekriteFaz 1
Laj 18 a 89 · Tout sèks · Mizajou Sep 14, 2026 · NCT07020806A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05837767Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05964504Biomarkers to Detect Endocrine Therapy Resistance
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06067503Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 16 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05269381Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05919108InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT05463796[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Jun 23, 2026 · NCT07432633A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
Ap rekriteFaz 2
Laj 50 ak plis · Fanm · Mizajou Jun 4, 2026 · NCT07483307Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Jan 20, 2026 · NCT06666439Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.